Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension.

Tello K, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, Roller F, Seeger W, Wilhelm J, Gall H, Richter MJ.

JACC Cardiovasc Imaging. 2019 Mar 8. pii: S1936-878X(19)30164-0. doi: 10.1016/j.jcmg.2018.12.032. [Epub ahead of print]

PMID:
30878422
2.

Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing.

Esfandiary A, Kutsche H, Schreckenberg R, Weber M, Pak O, Kojonazarov B, Sydykov A, Hirschhäuser C, Wolf A, Haag D, Hecker M, Fink L, Seeger W, Ghofrani HA, Schermuly RT, Weißmann N, Schulz R, Rohrbach S, Li L, Sommer N, Schlüter KD.

Cardiovasc Res. 2019 Mar 8. pii: cvz049. doi: 10.1093/cvr/cvz049. [Epub ahead of print]

PMID:
30850841
3.

Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population.

Kosanovic D, Platzek SM, Petrovic A, Sydykov A, Maripov A, Mamazhakypov A, Sartmyrzaeva M, Muratali Uulu K, Cholponbaeva M, Toktosunova A, Omurzakova N, Duishobaev M, Vroom C, Pak O, Weissmann N, Ghofrani HA, Sarybaev A, Schermuly RT.

Front Physiol. 2019 Feb 5;10:54. doi: 10.3389/fphys.2019.00054. eCollection 2019.

4.

Stem/Progenitor Cells in Cardiopulmonary Health, Disease, and Treatment.

Sharifpanah F, Ghofrani HA, Tsang SY, Sauer H.

Stem Cells Int. 2019 Jan 6;2019:9861403. doi: 10.1155/2019/9861403. eCollection 2019. No abstract available.

5.

Reply to "a pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension".

Tello K, Naeije R, Ghofrani HA, Gall H, Richter MJ.

Int J Cardiol. 2019 Mar 1;278:240-241. doi: 10.1016/j.ijcard.2018.12.040. No abstract available.

PMID:
30683327
6.

Multi-Beat Right Ventricular-Arterial Coupling During a Positive Acute Vaso-Reactivity Test.

Tello K, Dalmer A, Husain-Syed F, Seeger W, Naeije R, Ghofrani HA, Gall H, Richter MJ.

Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201809-1787IM. [Epub ahead of print] No abstract available.

PMID:
30645142
7.

Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding".

Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, Weissmann N, Stasch JP, Ghofrani HA, Seeger W, Schermuly RT, Novoyatleva T.

Biomed Res Int. 2018 Dec 16;2018:7491284. doi: 10.1155/2018/7491284. eCollection 2018. No abstract available.

8.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

PMID:
30632656
9.

Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload.

Tello K, Dalmer A, Axmann J, Vanderpool R, Ghofrani HA, Naeije R, Roller F, Seeger W, Sommer N, Wilhelm J, Gall H, Richter MJ.

Circ Heart Fail. 2019 Jan;12(1):e005512. doi: 10.1161/CIRCHEARTFAILURE.118.005512.

PMID:
30616360
10.

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).

Marra AM, Halank M, Benjamin N, Bossone E, Cittadini A, Eichstaedt CA, Egenlauf B, Harutyunova S, Fischer C, Gall H, Ghofrani HA, Hoeper MM, Lange TJ, Olsson KM, Klose H, Grünig E.

Respir Res. 2018 Dec 19;19(1):258. doi: 10.1186/s12931-018-0957-y.

11.

Evidence for Fucoidan-P-selectin Axis as a Therapeutic Target on Hypoxia-induced Pulmonary Hypertension.

Novoyatleva T, Kojonazarov B, Owczarek A, Veeroju S, Rai N, Henneke I, Böhm M, Grimminger F, Ghofrani HA, Seeger W, Weissmann N, Schermuly RT.

Am J Respir Crit Care Med. 2018 Dec 17. doi: 10.1164/rccm.201806-1170OC. [Epub ahead of print]

PMID:
30557519
12.

Chronic thromboembolic pulmonary hypertension.

Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801915. doi: 10.1183/13993003.01915-2018. Print 2019 Jan.

13.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

14.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

15.

Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography.

Kojonazarov B, Belenkov A, Shinomiya S, Wilchelm J, Kampschulte M, Mizuno S, Ghofrani HA, Grimminger F, Weissmann N, Seeger W, Schermuly RT.

Circ Cardiovasc Imaging. 2018 Dec;11(12):e007653. doi: 10.1161/CIRCIMAGING.118.007653.

PMID:
30525986
16.

Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?

Ghofrani HA.

Lancet Respir Med. 2019 Mar;7(3):191-193. doi: 10.1016/S2213-2600(18)30369-2. Epub 2018 Nov 23. No abstract available.

PMID:
30477764
17.

Cologne consensus conference on pulmonary hypertension - Update 2018.

Rosenkranz S, Ghofrani HA, Grünig E, Klose H, Olschewski H, Hoeper MM.

Int J Cardiol. 2018 Dec 1;272S:1-3. doi: 10.1016/j.ijcard.2018.09.064. Epub 2018 Sep 22. No abstract available.

PMID:
30344062
18.

Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension.

Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, Grimminger F, Grimminger J, Grünig E, Guth S, Halank M, Heine A, Hoeper MM, Klose H, Lange TJ, Meyer K, Neurohr C, Nickolaus K, Olsson KM, Opitz CF, Rosenkranz S, Seyfarth HJ, Warnke C, Wiedenroth C, Ghofrani HA, Ewert R.

J Heart Lung Transplant. 2018 Oct;37(10):1235-1244. doi: 10.1016/j.healun.2018.06.006. Epub 2018 Jun 21.

PMID:
30293617
19.

Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis.

Boehm M, Novoyatleva T, Kojonazarov B, Veit F, Weissmann N, Ghofrani HA, Seeger W, Schermuly RT.

Am J Respir Cell Mol Biol. 2019 Mar;60(3):346-356. doi: 10.1165/rcmb.2018-0069OC.

PMID:
30277804
20.

Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Sommer N, Droege F, Gamen KE, Geisthoff U, Gall H, Tello K, Richter MJ, Deubner LM, Schmiedel R, Hecker M, Spiekerkoetter E, Wirsching K, Seeger W, Ghofrani HA, Pullamsetti S.

Pulm Circ. 2019 Apr-Jun;9(2):2045894018805406. doi: 10.1177/2045894018805406. Epub 2018 Sep 27.

PMID:
30260738
21.

Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.

Hoeper MM, Apitz C, Grünig E, Halank M, Ewert R, Kaemmerer H, Kabitz HJ, Kähler C, Klose H, Leuchte H, Ulrich S, Olsson KM, Distler O, Rosenkranz S, Ghofrani HA.

Int J Cardiol. 2018 Dec 1;272S:37-45. doi: 10.1016/j.ijcard.2018.08.082. Epub 2018 Aug 25.

PMID:
30190158
22.

Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease.

Guth S, Wiedenroth CB, Rieth A, Richter MJ, Gruenig E, Ghofrani HA, Arlt M, Liebetrau C, Prüfer D, Rolf A, Hamm CW, Mayer E.

Eur Respir J. 2018 Sep 17;52(3). pii: 1800458. doi: 10.1183/13993003.00458-2018. Print 2018 Sep.

PMID:
30139773
23.

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial.

Richter MJ, Stollfuß B, Roitenberg A, Kleinjung F, Graeff V, Berghaus S, Müller C, Ghofrani HA.

Pulm Circ. 2018 Oct-Dec;8(4):2045894018798921. doi: 10.1177/2045894018798921. Epub 2018 Aug 20.

24.

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension.

Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum S, Rieth A, Hamm CW, Mayer E, Guth S, Liebetrau C.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018783996. doi: 10.1177/2045894018783996.

25.

Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels.

Strielkov I, Krause NC, Sommer N, Schermuly RT, Ghofrani HA, Grimminger F, Gudermann T, Dietrich A, Weissmann N.

Exp Physiol. 2018 Sep;103(9):1185-1191. doi: 10.1113/EP087117. Epub 2018 Jul 6.

PMID:
29917290
26.

Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension.

Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, Seeger W, Gall H, Richter MJ.

Int J Cardiol. 2018 Sep 1;266:229-235. doi: 10.1016/j.ijcard.2018.01.053.

PMID:
29887454
27.

Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers.

Sydykov A, Mamazhakypov A, Petrovic A, Kosanovic D, Sarybaev AS, Weissmann N, Ghofrani HA, Schermuly RT.

Front Physiol. 2018 May 23;9:609. doi: 10.3389/fphys.2018.00609. eCollection 2018. Review.

28.

Nintedanib in Severe Pulmonary Arterial Hypertension.

Richter MJ, Ewert J, Grimminger F, Ghofrani HA, Kojonazarov B, Petrovic A, Seeger W, Schermuly RT, Tello K, Gall H.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):808-810. doi: 10.1164/rccm.201801-0195LE. No abstract available.

PMID:
29763335
29.

More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension.

Tello K, Richter MJ, Axmann J, Buhmann M, Seeger W, Naeije R, Ghofrani HA, Gall H.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):816-818. doi: 10.1164/rccm.201802-0283LE. No abstract available.

PMID:
29756988
30.

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Gräf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Aldred M, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, MacKenzie Ross RV, Moledina S, Montani D, Newnham M, Olschewski A, Olschewski H, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Stein DF, Suntharalingam J, Swietlik EM, Toshner MR, van Heel DA, Vonk Noordegraaf A, Waisfisz Q, Wharton J, Wort SJ, Ouwehand WH, Soranzo N, Lawrie A, Upton PD, Wilkins MR, Trembath RC, Morrell NW.

Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.

31.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

32.

REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.

Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA.

J Heart Lung Transplant. 2018 Jul;37(7):836-843. doi: 10.1016/j.healun.2018.02.015. Epub 2018 Mar 1.

33.

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.

Cartin-Ceba R, Halank M, Ghofrani HA, Humbert M, Mattson J, Fritsch A, Krowka M.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018769305. doi: 10.1177/2045894018769305. Epub 2018 Mar 22.

34.

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.

Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, Weissmann N, Stasch JP, Ghofrani HA, Seeger W, Schermuly RT, Novoyatleva T.

Biomed Res Int. 2018 Jan 3;2018:3293584. doi: 10.1155/2018/3293584. eCollection 2018.

35.

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.

Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG, Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT, Kojonazarov B.

BMC Pulm Med. 2018 Mar 2;18(1):41. doi: 10.1186/s12890-018-0604-x.

36.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

37.

Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension.

Pak O, Scheibe S, Esfandiary A, Gierhardt M, Sydykov A, Logan A, Fysikopoulos A, Veit F, Hecker M, Kroschel F, Quanz K, Erb A, Schäfer K, Fassbinder M, Alebrahimdehkordi N, Ghofrani HA, Schermuly RT, Brandes RP, Seeger W, Murphy MP, Weissmann N, Sommer N.

Eur Respir J. 2018 Feb 1. pii: 1701024. doi: 10.1183/13993003.01024-2017. [Epub ahead of print]

PMID:
29419444
38.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

39.

Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease.

Wiedenroth CB, Olsson KM, Guth S, Breithecker A, Haas M, Kamp JC, Fuge J, Hinrichs JB, Roller F, Hamm CW, Mayer E, Ghofrani HA, Meyer BC, Liebetrau C.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217753122. doi: 10.1177/2045893217753122. Epub 2017 Dec 28.

40.

Beyond interleukin-6 in right ventricular function: Evidence for another biomarker.

Richter MJ, Ghofrani HA, Gall H.

J Heart Lung Transplant. 2018 May;37(5):674-675. doi: 10.1016/j.healun.2017.12.002. Epub 2017 Dec 7. No abstract available.

PMID:
29275141
41.

Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study.

Billar RJ, Leening MJG, Merkus D, Brusselle GGO, Hofman A, Stricker BHC, Ghofrani HA, Franco OH, Gall H, Felix JF.

Eur J Epidemiol. 2018 Apr;33(4):403-413. doi: 10.1007/s10654-017-0341-0. Epub 2017 Dec 13.

42.

Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation.

Bandorski D, Hoeltgen R, Becker N, Padberg W, Bogossian H, Wiedenroth C, Arlt M, Hamm C, Seeger W, Ghofrani HA, Hecker M, Gall H, Mayer K.

Biomed Res Int. 2017;2017:4519796. doi: 10.1155/2017/4519796. Epub 2017 Nov 6.

43.

Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study.

Loth DW, Lahousse L, Leening MJG, Krijthe BP, Felix JF, Gall H, Hofman A, Ghofrani HA, Franco OH, Stricker BH, Brusselle GG.

Respir Med. 2017 Nov;132:50-55. doi: 10.1016/j.rmed.2017.09.009. Epub 2017 Sep 21.

PMID:
29229105
44.

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.

Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM.

J Heart Lung Transplant. 2018 Apr;37(4):513-519. doi: 10.1016/j.healun.2017.11.006. Epub 2017 Nov 11.

45.

Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk.

Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R.

Sci Transl Med. 2017 Nov 15;9(416). pii: eaai9048. doi: 10.1126/scitranslmed.aai9048.

PMID:
29141888
46.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
47.

Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy.

Guth S, Wiedenroth CB, Wollenschläger M, Richter MJ, Ghofrani HA, Arlt M, Mayer E.

J Thorac Cardiovasc Surg. 2018 Feb;155(2):643-649. doi: 10.1016/j.jtcvs.2017.09.045. Epub 2017 Sep 20.

PMID:
29033041
48.

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators.

Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11.

PMID:
28919201
49.

ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.

Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, Weissmann N, Seeger W, Liles JT, Schermuly RT.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. doi: 10.1164/rccm.201703-0502OC.

PMID:
28910144
50.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

Supplemental Content

Loading ...
Support Center